1
Bharat B Aggarwal, Michael A Palladino, Mohamed R Shalaby: Tumor necrosis factor antagonists and their use. Genentech, Diane L Marschang, August 18, 1998: US05795967 (168 worldwide citation)

Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis fac ...


2
Bharat B Aggarwal, Michael A Palladino, Mohamed R Shalaby: Tumor necrosis factor antagonists and their use. Genentech, Diane L Marschang, September 30, 1997: US05672347 (103 worldwide citation)

Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis fac ...


3
James A Wells, Brian C Cunningham: Method for identifying active domains and amino acid residues in polypeptides and hormone variants. Genentech, Timothy R Schwartz, Diane L Marschang, November 10, 1998: US05834250 (98 worldwide citation)

The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polyp ...


4
William Matthews, Timothy W Austin: Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides. Genentech, Craig G Svoboda, Diane L Marschang, December 22, 1998: US05851984 (94 worldwide citation)

Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation or differentiation of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.


5
Ralph H Schwall, Kelly Helen Tabor: Hepatocyte growth factor receptor antagonist antibodies and uses thereof. Genentech, Diane L Marschang, November 11, 1997: US05686292 (61 worldwide citation)

Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF recept ...


6
Avi J Ashkenazi: Apo-2-receptor. Genentech, Diane L Marschang, January 29, 2002: US06342369 (43 worldwide citation)

Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.


7
Avi J Ashkenazi: Apo-2 ligand. Genentech, Diane L Marschang, February 29, 2000: US06030945 (42 worldwide citation)

A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. M ...


8
Steven Chamow, Nishit Modi, Ralph Schwall, Thomas Zioncheck: Inhibition of heparin-binding. Genentech, Diane L Marschang, Ginger R Dreger, November 7, 1995: US05464815 (30 worldwide citation)

The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the ...


9
Paul J Godowski, Natalie A Lokker, Melanie R Mark: Hepatocyte growth factor variants. Genentech, Diane L Marschang, August 20, 1996: US05547856 (28 worldwide citation)

The invention concerns hepatocyte growth factor (HGF) amino acid sequence variants. The preferred variants are resistant to proteolytic cleavage by enzymes capable of in vivo conversion of HGF into its two-chain form and/or contain a mutation within the protease domain of HGF.


10
Barbara H O Connor, James Q Oeswein: Human growth hormone aqueous formulation. Genentech, Diane L Marschang, June 9, 1998: US05763394 (27 worldwide citation)

A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations ...